Home » Archive by Category


San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Aptose Biosciences To Host Conference Call And Webcast For Four Month Interim Period Ended September 30, 2014

October 30, 2014 – 5:00 am | Edit Post

SAN DIEGO and TORONTO, Oct. 30, 2014 /PRNewswire/ – Aptose Biosciences Inc. (Aptose) (NASDAQ: APTO; TSX:APS), a clinical-stage company developing targeted agents and molecular diagnostics to treat the underlying mechanisms of cancer, today announced it intends…

Immunomedics, Inc. Provides Update On Phase 2 Study Of Isactuzumab Govitecan In Patients With Diverse Metastatic Solid Cancers

October 30, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 29, 2014 (GLOBE NEWSWIRE) — Immunomedics, Inc., (Nasdaq:IMMU) today announced that isactuzumab govitecan (IMMU-132), the Company’s proprietary solid-tumor antibody-drug conjugate (ADC), continues to produce encouraging results in a Phase 2 clinical trial in heavily…

Fate Therapeutics To Present At Nomura Biotechnology Conference

October 30, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 30, 2014 (GLOBE NEWSWIRE) — Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer will…

Neurocrine Biosciences, Inc. Receives Breakthrough Therapy Designation For NBI-98854 In Tardive Dyskinesia

October 30, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 30, 2014 /PRNewswire/ –Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its Vesicular Monoamine Transporter 2 inhibitor, NBI-98854, in tardive dyskinesia. A breakthrough therapy designation…

GreatCall Adds AliveCor Heart Monitor To Mobile Health Portfolio

October 30, 2014 – 5:00 am | Edit Post

Connection to Touch3 smartphone brings mobile heart health tracking directly to patients and their physicians SAN DIEGO October 30, 2014 GreatCall, Inc., the leader in creating mobile health and safety solutions for active aging, is bringing the ability to affordably track heart health anywhere, anytime to its Touch3 smartphone as a pilot program. The AliveCor Heart Monitor…

Volcano Corporation Schedules Third Quarter Conference Call, Webcast

October 30, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 29, 2014 /PRNewswire/ –Volcano Corporation (Nasdaq: VOLC), a leading company focused on improving patient and economic outcomes on a global basis by developing and delivering innovative minimally invasive coronary and peripheral visualization, physiology diagnostics and therapies, today announced…

Ciclofilin Pharmaceuticals Appoints To Its Board Of Directors

October 30, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 30, 2014 (GLOBE NEWSWIRE) — Ciclofilin Pharmaceuticals Inc. (“Ciclofilin” or the “Company”), a developer of broad spectrum antiviral medications, announced today the appointment of Michael Kamdar as a new member of the Company’s Board of Directors. Mr. Kamdar has more than …

Isis Pharmaceuticals, Inc. To Present At The

October 30, 2014 – 5:00 am | Edit Post

CARLSBAD, Calif., Oct. 30, 2014 /PRNewswire/ — Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Nomura Biotechnology Conference on Thursday, November 6, 2014 at

Ambit Biosciences Announces Expiration Of Hart-Scott-Rodino Waiting Period

October 30, 2014 – 5:00 am | Edit Post

SAN DIEGO, Oct. 28, 2014 /PRNewswire/ — Ambit Biosciences Corporation (hereinafter, Ambit Biosciences) (NASDAQ: AMBI) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR”) in connection with Daiichi Sankyo’s previously announced tender offer…

Enzyme could help explain life’s origin

October 29, 2014 – 10:20 pm | Edit Post

Enzyme made by Scripps Research scientists could lead to new class of therapies.